• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 20 Nov

    BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

    POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global LLC(“ProgenaCare”), a… Read More..

    Share this:
  • 18 Nov

    Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

    Toronto, ON – November 18, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label… Read More..

    Share this:
  • 18 Nov

    AmpliTech Group’s AmpliTech Inc. Division Secures Initial Purchase Order Under 5-Year Basic Order Agreement With Fortune 1000 U.S. Company

    HAUPPAUGE, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for… Read More..

    Share this:
« Previous 1 … 42 43 44 45 46 … 243 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact